InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: ignatiusrielly35 post# 46857

Wednesday, 05/22/2019 8:52:06 AM

Wednesday, May 22, 2019 8:52:06 AM

Post# of 48316
I agree, this is positive. TNBC is a tough nut to crack and 20% response rates beats Keytruda monotherapy with 5%. Merck was the one who showed interest in TNBC combo therapy with Oncosec. PISCES can get an accelerated approval with a 20% BORR....and so can TNBC here in combo therapy. Merck will definitely be interested in Oncosec for these indications.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCSQ News